Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage

Table 1

Demographic and clinical characteristics of uterine LMS patients stratified by receipt of chemotherapy.

Characteristics	Chemotherapy		No chemotherapy
	Number	%	Number	%
Age at diagnosis, y					<0.0001
18–39	66	7.1	107	6.0
40–49	270	28.8	467	26.0
50–64	475	50.7	794	44.2
65+	125	13.4	428	23.8
Race (missing from analysis: )					0.7531
White	701	79.7	1327	78.4
African American	179	20.3	365	21.6
Hispanic (missing from analysis: )					0.0292
Yes	79	8.8	111	6.5
No	814	91.2	1596	93.5
Comorbidities (Charlson/Deyo score)					0.1509
0	787	84.1	1460	81.3
1	126	13.5	275	15.3
2	23	2.5	61	3.4
Insurance status (missing from analysis: )					<0.0001
Medicare	122	13.2	442	24.9
Private	657	71.0	1112	62.8
Medicaid/Other government	89	9.6	120	6.8
None	57	6.2	98	5.5
Median household income ($) (missing from analysis: )					0.4726
<38,000	164	17.7	329	18.6
38,000–47,999	198	21.4	366	20.7
48,000–62,999	252	27.2	441	24.9
>63,000	311	33.6	634	35.8
Education (% no high school diploma) (missing from analysis: )					0.0355
≥21	166	17.9	321	18.1
13–20.9	185	20.0	437	24.7
7–12.9	335	36.2	576	32.5
<7	239	25.8	436	24.6
Location of patient (missing from analysis: )					0.0902
Large metropolitan	574	62.7	1013	58.7
Small metropolitan	236	25.8	484	28.0
Suburban	75	8.2	145	8.4
Rural	30	3.3	85	4.9
Hospital volume (cases per year)					0.0181
0.09	38	4.1	99	5.5
0.18–0.27	103	11.0	256	14.3
0.36–0.55	181	19.3	353	19.7
0.64–7.27	614	65.6	1088	60.6
Regional lymph nodes positive (missing from analysis: )					<0.0001
Yes	30	8.0	13	2.0
No	347	92.0	642	98.0
Stage					<0.0001
1	676	72.2	1541	85.8
2	64	6.8	116	6.5
3	196	20.9	139	7.7
Year of diagnosis					<0.0001
2004–2009	345	36.9	1005	56.0
2010–2014	591	63.1	791	44.0
Radiation (missing from analysis: )					0.0406
Yes	225	24.3	373	20.9
No	700	75.7	1413	79.1
Oophorectomy (missing from analysis: )					0.6492
Yes	716	84.0	1437	84.7
No	136	16.0	259	15.3